TLR4 has a tumor-promoting effect [56]; however, monophosphoryl lipid A, a TLR4 agonist, enhances the adaptive immune response by promoting Th1 cell differentiation and increasing IFN-γ expression levels [57]. Here, IFNG is linked to neoplasm.